Two major drugmakers are trying to convince employers to cover the cost of their pricey weight-loss medications to save on health care spending in the long run.
The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year, the Wall Street Journal reported Tuesday.
